 | Up a level |
2016
Sehouli, J., Mahner, S., Neunhoeffer, T., Harter, P., de Gregorio, N., Fridrich, C., Markmann, S., Richter, R., Potenberg, J., Lorenz, R., Schmidt, M., Doering, G., Belau, A., Lueck, H. J., Chekerov, R., du Bois, A. and Hilpert, F. (2016). Topotecan (T) +/- Sorafenib (S) for platinum-resistant ovarian cancer (PROC): results of doubleblind placebo-controlled randomized NOGGO - AGO intergroup trial. Int. J. Gynecol. Cancer, 26. S. 2 - 4. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1525-1438
Wirtz, M., Thangarajah, F., Ufhaas, A., Puppe, J., Richters, L., Ratio, D., Fridrich, C., Morgenstern, E. and Mailmann, P. (2016). Experiences with off-lable use of bevacizumab in patients with first-diagnosed locally advanced and metastatic cervical cancer. Oncol. Res. Treat., 39. S. 99 - 100. BASEL: KARGER. ISSN 2296-5262
2015
Wirtz, M., Thangarajah, F., Ulhaas, A., Puppe, J., Richters, J., Ratiu, D., Fridrich, C., Morgenstern, B. and Mallmann, P. (2015). EXPERIENCES WITH OFF-LABLE USE OF BEVACIZUMAB IN PATIENTS WITH FIRST-DIAGNOSED LOCALLY ADVANCED AND METASTATIC CERVICAL CANCER. Int. J. Gynecol. Cancer, 25 (9). S. 1181 - 1182. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1525-1438
2014
Kraemer, S., Malter, W., Lange, N., Fridrich, C. and Mallmann, P. (2014). Targeted breast surgery - classification of oncoplastic techniques. Oncol. Res. Treat., 37. S. 16 - 17. BASEL: KARGER. ISSN 2296-5262